The Role of Positron Emission Tomography With 68Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy

Urology

Volumn 95, Issue , 2016, Pages 11-15

  Rai, Bhavan Prasad ^a   Baum, Richard Paul ^b   Patel, Amit ^a   Hughes, Robert ^c   Alonzi, Roberto ^c   Lane, Tim ^a   Adshead, Jim ^a   Vasdev, Nikhil ^a  

^a LISTER HOSPITAL   (United Kingdom)

^b ZENTRALKLINIK BAD BERKA   (Germany)

^c MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

ADVANCED CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; HUMAN; LYMPH NODE; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; THERANOSTIC NANOMEDICINE; DIAGNOSTIC IMAGING; PATHOLOGY; PREOPERATIVE CARE; PROCEDURES; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

ANTIGENS, SURFACE; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84959870707     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2015.12.048     Document Type: Review

References (26)

1. 1 Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol 65 (2014), 124–137.
2. 2 Salami, S.S., Ben-Levi, E., Yaskiv, O., et al. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?. BJU Int 115 (2015), 562–570.
3. 3 Hovels, A.M., Heesakkers, R.A., Adang, E.M., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63 (2008), 387–395.
4. 4 Umbehr, M.H., Müntener, M., Hany, T., Sulser, T., Bachmann, L.M., The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64 (2013), 106–117.
5. 5 Fuccio, C., Castellucci, P., Schiavina, R., et al. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol 81 (2012), e893–e896.
6. 6 Giovacchini, G., Picchio, M., Coradeschi, E., et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 37 (2010), 301–309.
7. 7 Picchio, M., Briganti, A., Fanti, S., et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 59 (2011), 51–60.
8. 8 Eder, M., Eisenhut, M., Babich, J., Haberkorn, U., PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 40 (2013), 819–823.
9. 9 Ghosh, A., Heston, W.D., Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91 (2004), 528–539.
10. 10 Hellwig, D., Moosbauer, J., Eilles, C., Ga-68-PSMA PET/CT for prostate cancer. Aktuelle Urol 45 (2014), 457–463.
11. 11 Bostwick, D.G., Pacelli, A., Blute, M., Roche, P., Murphy, G.P., Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82 (1998), 2256–2261.
12. 12 Bander, N.H., Trabulsi, E.J., Kostakoglu, L., et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 170 (2003), 1717–1721.
13. 13 Banerjee, S.R., Pullambhatla, M., Byun, Y., et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 53 (2010), 5333–5341.
14. 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 41 (2014), 887–897.
15. 15 Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65 (2014), 467–479.
16. 16 Jereczek-Fossa, B.A., Beltramo, G., Fariselli, L., et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82 (2012), 889–897.
17. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56 (2015), 668–674.
18. 18 Afshar-Oromieh, A., Zechmann, C.M., Malcher, A., et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41 (2014), 11–20.
19. 19 Giesel, F.L., Fiedler, H., Stefanova, M., et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42 (2015), 1794–1800.
20. 20 Briganti, A., Blute, M.L., Eastham, J.H., et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 55 (2009), 1251–1265.
21. 21 Eiber, M., Maurer, T., Beer, A., et al. Prospective evaluation of PSMA-PET imaging for preoperative lymph node staging in prostate cancer. J Nucl Med, 55(1_MeetingAbstracts), 2014, 20.
22. 22 Budäus, L., Leyh-Bannurah, S., Salomon, G., et al. Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol, 2015, 10.1016/j.eururo.2015.06.010.
23. 23 Herrmann, K., Lapa, C., Wester, H.J., et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med 56 (2015), 410–416.
24. 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56 (2015), 1169–1176.
25. 25 Baum, R.P., Kulkarni, H.R., Schuchardt, C., et al. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy [e-pub ahead of print]. J Nucl Med, 2016 PII: jnumed.115.168443. PubMed PMID: 26795286.
26. 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?. Int J Urol 21 (2014), 1286–1288.